Citius Oncology(CTOR.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Citius Oncology
CTOR.US
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey.
1.850 T
CTOR.USMarket value -Rank by Market Cap -/-

Financial Score

21/05/2026 Update
D
BiotechnologyIndustry
Industry Ranking0/385
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-47.41%E
    • Profit Margin-599.28%E
    • Gross Margin79.99%A
  • Growth ScoreC
    • Revenue YoY0.00%D
    • Net Profit YoY-2.41%C
    • Total Assets YoY21.54%A
    • Net Assets YoY41.47%A
  • Cash ScoreC
    • Cash Flow Margin54.35%C
    • OCF YoY0.00%D
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreC
    • Gearing Ratio46.88%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Citius Oncology | 8-K: FY2026 Q2 Revenue: USD 1.667 M

    Earnings Watch·
    US
    CTOR
    -0.27%
    Earnings Watch·
    US
    CTOR
    -0.27%

    16:30 ETCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

    prnewswire·
    US
    CTXR
    +4.66%
    US
    PBE
    +1.60%
    US
    BBH
    +0.96%
    prnewswire·
    US
    CTXR
    +4.66%
    US
    PBE
    +1.60%
    US
    BBH
    +0.96%

    Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | CTOR Stock News

    StockTitan·
    US
    CTOR
    -0.27%
    StockTitan·
    US
    CTOR
    -0.27%

    Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility

    Tip Ranks·
    US
    CTXR
    +4.66%
    US
    CTOR
    -0.27%
    US
    LABU
    +11.76%
    Tip Ranks·
    US
    CTXR
    +4.66%
    US
    CTOR
    -0.27%
    US
    LABU
    +11.76%

    Citius raises $36.5m for Lymphir commercialisation

    Pharmaceutical Technology·
    US
    CTXR
    +4.66%
    Pharmaceutical Technology·
    US
    CTXR
    +4.66%
    © 2026 Longbridge｜Disclaimer